Stocktoria
SPRUCE BIOSCIENCES, INC. SPRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-09
Chart by TradingView
5/9
Piotroski F — financial health
-12.96
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $4.9M | $10.1M | $0 | — |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | -$42.1M |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | -$42.3M |
| Operating cash flow | $33.3M | -$56.0M | -$33.3M | -$41.7M | -$35.9M |
| Free cash flow | — | -$56.0M | -$33.3M | -$41.7M | -$36.0M |
| Total assets | $53.0M | $45.2M | $103.9M | $85.6M | $126.5M |
| Total liabilities | $10.5M | $16.4M | $27.4M | $17.2M | $15.1M |
| Shareholders' equity | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M |
| Ratios | |||||
| Operating margin | — | -1143.4% | -515.3% | — | — |
| Net margin | — | -1079.9% | -475.0% | — | — |
| FCF margin | — | -1139.6% | -329.9% | — | — |
| Return on assets | -73.5% | -117.3% | -46.1% | -53.9% | -33.4% |
| Return on equity | -91.7% | -184.0% | -62.6% | -67.4% | -38.0% |
| Debt / equity | 0.00× | 0.00× | 0.02× | 0.05× | 0.04× |
| Current ratio | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 |
| Revenue growth | -100.0% | -51.3% | — | — | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.96 (distress)
- Working capital / assets 0.793
- Retained earnings / assets -5.455
- EBIT / assets -0.689
- Equity / liabilities 4.047
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001683553 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.